Literature DB >> 9596761

Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine.

G Vidarsson1, S T Sigurdardottir, T Gudnason, S Kjartansson, K G Kristinsson, G Ingolfsdottir, S Jonsson, H Valdimarsson, G Schiffman, R Schneerson, I Jonsdottir.   

Abstract

Streptococcus pneumoniae is a major respiratory pathogen of infants, children, and the elderly. Polysaccharide vaccines have been useful in adult populations but do not elicit protective immunity in infants and young children. To enhance their immunogenicity, vaccines of pneumococcal polysaccharides conjugated to proteins are being developed. In this study antibody levels and opsonic activities were compared in sera of infants and adults injected with pneumococcal polysaccharide type 6B (Pn6B) conjugated to tetanus toxoid (TT) (Pn6B-TT). Healthy infants were injected with Pn6B-TT; group A was injected at 3, 4, and 6 months of age, and group B was injected at 7 and 9 months of age. A booster injection was given at 18 months. Adults were injected once. Antibodies were measured by enzyme-linked immunosorbent assay and radioimmunoassay, and their functional activities were measured by opsonophagocytosis of radiolabelled pneumococci. In adults, increases in immunoglobulin M (IgM), IgG, IgA, IgG1, and IgG2 to Pn6B were observed. Infants reached adult levels of IgG1 anti-Pn6B after the primary injections. After the booster injection the infant groups had total IgG- and IgM-Pn6B antibody levels similar to those of adults. After the booster injection, IgG1 was the dominant infant anti-Pn6B isotype and at a level higher than in vaccinated adults, but IgA and IgG2 antibodies remained at very low levels. Opsonic activity increased significantly after Pn6B-TT injections; the highest infant sera showed opsonic activity comparable to that of vaccinated adults. Overall, opsonic activity correlated best with total and IgG anti-Pn6B antibodies (r = 0.741, r = 0.653, respectively; n = 35) and was highest in sera with high levels of all Pn6B antibody isotypes. The results indicate the protective potential of a pneumococcal 6B polysaccharide protein conjugate vaccine for young infants.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596761      PMCID: PMC108283          DOI: 10.1128/IAI.66.6.2866-2870.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Immunisation of infants in Iceland against Haemophilus influenzae type b.

Authors:  K E Jónsdóttir; O Steingrímsson; O Olafsson
Journal:  Lancet       Date:  1992-07-25       Impact factor: 79.321

Review 2.  Human antibody effector function.

Authors:  D R Burton; J M Woof
Journal:  Adv Immunol       Date:  1992       Impact factor: 3.543

Review 3.  The mechanism by which microorganisms avoid complement attack.

Authors:  M M Frank
Journal:  Curr Opin Immunol       Date:  1992-02       Impact factor: 7.486

4.  The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.

Authors:  Y M Lucisano Valim; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

5.  IgG subclass response and opsonization of Streptococcus pneumoniae after vaccination of healthy adults.

Authors:  E Bardardottir; S Jonsson; I Jonsdottir; A Sigfusson; H Valdimarsson
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

6.  Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults.

Authors:  J E Lortan; A S Kaniuk; M A Monteil
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

7.  Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.

Authors:  R Schneerson; J B Robbins; J C Parke; C Bell; J J Schlesselman; A Sutton; Z Wang; G Schiffman; A Karpas; J Shiloach
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

8.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

9.  Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine.

Authors:  A K Takala; J Eskola; M Leinonen; H Käyhty; A Nissinen; E Pekkanen; P H Mäkelä
Journal:  J Infect Dis       Date:  1991-11       Impact factor: 5.226

10.  A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding.

Authors:  P A Warmerdam; J G van de Winkel; A Vlug; N A Westerdaal; P J Capel
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

View more
  22 in total

1.  Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.

Authors:  M Anttila; M Voutilainen; V Jäntti; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 2.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

3.  Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children.

Authors:  Anu Soininen; Maijastiina Karpala; Sirkka-Liisa Wahlman; Hannele Lehtonen; Helena Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

4.  Immune profile of asplenic patients following single or double vaccine administration: A longitudinal cross-sectional study.

Authors:  Sait Murat Doğan; Ahmet Aykas; Evrim Şefika Yücel; Gökalp Okut; Cenk Şimşek; Kürşat Çayhan; Baha Zengel; Adam Uslu
Journal:  Ulus Cerrahi Derg       Date:  2015-04-09

5.  Phenotypic analysis of pneumococcal polysaccharide-specific B cells.

Authors:  Noor Khaskhely; Jason Mosakowski; Rebecca S Thompson; Sadik Khuder; S Louise Smithson; M A Julie Westerink
Journal:  J Immunol       Date:  2012-01-23       Impact factor: 5.422

6.  Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Authors:  F M Russell; J R Carapetis; R L Burton; J Lin; P V Licciardi; A Balloch; L Tikoduadua; L Waqatakirewa; Y B Cheung; M L K Tang; M H Nahm; E K Mulholland
Journal:  Vaccine       Date:  2010-10-31       Impact factor: 3.641

7.  Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations.

Authors:  Saeyoung Park; Moon H Nahm
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

8.  Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine.

Authors:  Birgit Simell; Anu Nurkka; Nina Ekström; Noga Givon-Lavi; Helena Käyhty; Ron Dagan
Journal:  Clin Vaccine Immunol       Date:  2012-08-08

9.  Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable?

Authors:  M Väkeväinen; W Jansen; E Saeland; I Jonsdottir; H Snippe; A Verheul; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

10.  Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide.

Authors:  Tamika Burns; Maria Abadi; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.